Andrew Talal, MD, MPH is a physician-scientist with more than 20 years’ experience in treating hepatitis C virus (HCV), especially among substance users. He is currently Professor of Medicine at SUNY, University at Buffalo where he has been the principal investigator on a 7-year, $8 million award from the Patient-Centered Outcomes Research Institute to study a facilitated telemedicine model-based HCV treatment among patients in treatment for opioid use disorder. The study consists of 12 telemedicine sites across New York State conducting integrated treatment of HCV and opiate use disorder. The study has also been supported by ~$4 million from the Kaleida Health Foundation over the past 8 years. Dr. Talal was also appointment by the New York Governor to a task force to develop a statewide HCV elimination plan and he also serves on the NYS HCV Guidelines committee. He also has active funding from the NIH to study factors leading to HCV elimination, and he is a practicing physician evaluating patients for liver diseases.

Andrew has the following Disclosures: 

Grant/Research Support

Merck, Gilead, Abbott Laboratories, Intercept, Genfit, BMS, Eli Lilly and Co.

Committee /Advisor

Gilead

Speaker’s Bureau

Chronic Liver Disease Foundation